Developed by Novartis for treatment as an immunosuppressant to prevent rejection of organ transplants. Afinitor is also indicated for a number of cancers including renal and breast cancer.
Afinitor is positive and engaging with both patient and prescriber appeal. Powerful and strong sounding the name is derived from ‘affinity’; the re-assuring tone suggests trust, confidence and innovation.
